Login Register Cart 0
Generic placeholder image

Clinical Cancer Drugs

Editor-in-Chief

ISSN (Print): 2212-697X
ISSN (Online): 2212-6988

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Neurotoxicity of Cisplatin as Monotherapy or Combined Chemotherapy in Cancer Treatment

Author(s): André Nunes Volpini, Igor José de Souza Marques and Iago Dillion Lima Cavalcanti*

Volume 9, Issue 1, 2022

Published on: 01 July, 2022

Article ID: e290622206511 Pages: 13

DOI: 10.2174/2212697X09666220629161535

Price: $65

Abstract

Introduction: The main toxicity of cisplatin is nephrotoxicity, but more and more studies have highlighted and unveiled the mechanisms of cisplatin toxicity, and the neurotoxicity has been standing out.

Objective: We aimed to bring together the main studies that highlight the neurotoxicity of cisplatin in the treatment of cancer patients.

Methods: We performed a literature review using the keywords “Neurotoxicity”, “Cisplatin”, “Oncology Therapy”, and “Chemotherapy” in the SciELO, PubMed, Sciencedirect, MEDLINE, Scifinder, and CAplus databases.

Results: We selected 60 articles published between 1983 and 2021 that report the mechanisms of cisplatin toxicity or which provide clinical data on the neurotoxicity profile of cisplatin as monotherapy and as a combination therapy, highlighting that one of the main neurotoxicity of cisplatin is in the development of peripheral neuropathy.

Conclusion: Cisplatin is neurotoxic and can induce the development of peripheral neuropathy and the combination with neurotoxic drugs such as paclitaxel and vincristine only contributes to the increase in neurological toxicity. Thus, we emphasize the importance of evaluating the neurotoxicity of cisplatin, especially in patients who use protocols that contain other antineoplastic agents that are also neurotoxic.

Keywords: Neurotoxicity, cisplatin, oncology therapy, chemotherapy, combined chemotherapy, monotherapy, peripheral neuropathy.

[1]
Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 2015; 596: 90-107.
[http://dx.doi.org/10.1016/j.neulet.2014.10.014] [PMID: 25459280]
[2]
Serinan E, Altun Z, Aktas S, Çeçen E, Olgun N. Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity. J Int Adv Otol 2017.
[http://dx.doi.org/10.5152/iao.2018.4097] [PMID: 29460824]
[3]
Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. J Med 2012; 70(1): 18-25.
[PMID: 22271810]
[4]
Pollard KJ, Bolon B, Moore MJ. Comparative Analysis of Chemotherapy-Induced Peripheral Neuropathy in Bioengineered Sensory Nerve Tissue Distinguishes Mechanistic Differences in Early-Stage Vincristine-, Cisplatin-, and Paclitaxel-Induced Nerve Damage. Toxicol Sci 2021; 180(1): 76-88.
[http://dx.doi.org/10.1093/toxsci/kfaa186] [PMID: 33410881]
[5]
Owoeye O, Adedara IA, Farombi EO. Pretreatment with taurine prevented brain injury and exploratory behaviour associated with administration of anticancer drug cisplatin in rats. Biomed Pharmacother 2018; 102: 375-84.
[http://dx.doi.org/10.1016/j.biopha.2018.03.051] [PMID: 29571023]
[6]
Tundo GR, Sbardella D, Ciaccio C, et al. Effect of cisplatin on proteasome activity. J Inorg Biochem 2015; 153: 253-8.
[http://dx.doi.org/10.1016/j.jinorgbio.2015.08.027] [PMID: 26387966]
[7]
Friesland A, Weng Z, Duenas M, Massa SM, Longo FM, Lu Q. Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR. Neurotoxicology 2014; 45: 81-90.
[http://dx.doi.org/10.1016/j.neuro.2014.09.005] [PMID: 25277379]
[8]
Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 1999; 99(9): 2467-98.
[http://dx.doi.org/10.1021/cr980421n] [PMID: 11749487]
[9]
Fontes APS, Almeida SG, Nader LA. Compostos de Platina em Quimioterapia do Câncer. Quim Nova 1997; 20(4): 398-406.
[http://dx.doi.org/10.1590/S0100-40421997000400010]
[10]
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019.88102925
[http://dx.doi.org/10.1016/j.bioorg.2019.102925] [PMID: 31003078]
[11]
Pubchem. Cisplatin. National Library of Medicine - NIH. 2021. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5702198 Access in: April 7, 2021.
[12]
Drugbank. Cisplatin. . 2021. Available from: https://go.drugbank.com/drugs/DB00515 Access in: April 7, 2021.
[13]
Jia YY, Zhang JJ, Zhang YX, et al. Construction of redox-responsive tumor targeted cisplatin nano-delivery system for effective cancer chemotherapy. Int J Pharm 2020.580119190
[http://dx.doi.org/10.1016/j.ijpharm.2020.119190] [PMID: 32151664]
[14]
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]
[15]
Aggarwal SK. Calcium modulation of toxicities due to Cisplatin. Met Based Drugs 1998; 5(2): 77-81.
[http://dx.doi.org/10.1155/MBD.1998.77] [PMID: 18475826]
[16]
Saad SY, Najjar TA, Alashari M. Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats. Clin Exp Pharmacol Physiol 2004; 31(12): 862-7.
[http://dx.doi.org/10.1111/j.1440-1681.2004.04127.x] [PMID: 15659050]
[17]
Nuñez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998; 17(25): 3237-45.
[http://dx.doi.org/10.1038/sj.onc.1202581] [PMID: 9916986]
[18]
Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007; 96(9): 2181-96.
[http://dx.doi.org/10.1002/jps.20874] [PMID: 17593552]
[19]
Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 2011; 10(7): 1161-72.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-1100] [PMID: 21566064]
[20]
Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984; 100(5): 704-13.
[http://dx.doi.org/10.7326/0003-4819-100-5-704] [PMID: 6370067]
[21]
Spreckelmeyer S, Orvig C, Casini A. Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin. Molecules 2014; 19(10): 15584-610.
[http://dx.doi.org/10.3390/molecules191015584] [PMID: 25268716]
[22]
Modur V, Joshi P, Nie D, Robbins KT, Khan AU, Rao K. CD24 expression may play a role as a predictive indicator and a modulator of cisplatin treatment response in head and neck squamous cellular carcinoma. PLoS One 2016; 11(6)e0156651
[http://dx.doi.org/10.1371/journal.pone.0156651] [PMID: 27276062]
[23]
Azzoli CG. Baker JrS, Temin S, Pao W, Aliff T, Brahmer J. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer. J Clin Oncol 2009; 27(36): 6251-66.
[http://dx.doi.org/10.1200/JCO.2009.23.5622]
[24]
Pirker R, Filipits M. Cetuximab in non-small-cell lung cancer. Transl Lung Cancer Res 2012; 1(1): 54-60.
[http://dx.doi.org/10.3978/j.issn.2218-6751.11.01] [PMID: 25806155]
[25]
Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30(14): 1692-8.
[http://dx.doi.org/10.1200/JCO.2011.40.4905] [PMID: 22473169]
[26]
Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 2016; 102: 37-46.
[http://dx.doi.org/10.1016/j.critrevonc.2016.03.014] [PMID: 27105947]
[27]
Eroglu A, Kocaoglu H, Demirci S, Akgül H. Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity. Eur J Surg Oncol 2000; 26(3): 213-21.
[http://dx.doi.org/10.1053/ejso.1999.0779] [PMID: 10753532]
[28]
Edmonson JH, Petersen IA, Shives TC, et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer 2002; 94(3): 786-92.
[http://dx.doi.org/10.1002/cncr.10259] [PMID: 11857314]
[29]
Wang J, Xu R, Li J, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 2016; 19(1): 234-44.
[http://dx.doi.org/10.1007/s10120-015-0457-4] [PMID: 25604851]
[30]
Chhetri P, Giri A, Shakya S, Shakya S, Sapkota B, Pramod KC. Current development of anti-cancer drug S-1. J Clin Diagn Res 2016; 10(11): XE01-5.
[http://dx.doi.org/10.7860/JCDR/2016/19345.8776] [PMID: 28050491]
[31]
Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4(7): 501-10.
[http://dx.doi.org/10.1016/S2468-1253(19)30083-4] [PMID: 31101534]
[32]
Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014; 32(18): 1895-901.
[http://dx.doi.org/10.1200/JCO.2013.53.2465] [PMID: 24821881]
[33]
Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. International Journal of Radiation Oncology *Biology* Physics 2007; 68(4): 1072-80.
[http://dx.doi.org/10.1016/j.ijrobp.2007.01.054]
[34]
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068-77.
[http://dx.doi.org/10.1200/JCO.2000.18.17.3068] [PMID: 11001674]
[35]
Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3(7): 756-63.
[http://dx.doi.org/10.1097/JTO.0b013e31817c73d6] [PMID: 18594322]
[36]
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23(34): 8646-54.
[http://dx.doi.org/10.1200/JCO.2005.02.4646] [PMID: 16314626]
[37]
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357(17): 1705-15.
[http://dx.doi.org/10.1056/NEJMoa070956] [PMID: 17960013]
[38]
Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357(17): 1695-704.
[http://dx.doi.org/10.1056/NEJMoa071028] [PMID: 17960012]
[39]
Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12(4): 701-6.
[http://dx.doi.org/10.1200/JCO.1994.12.4.701] [PMID: 7512129]
[40]
Aldossary SA. Review on pharmacology of cisplatin: Clinical use, toxicity and mechanism of resistance of cisplatin. Biomed Pharmacol J 2019; 12(1): 7-15.
[http://dx.doi.org/10.13005/bpj/1608]
[41]
Mead GM, Stenning SP. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clinical oncology (Royal College of Radiologists (Great Britain)) 1997; 9(4): 207-9.
[http://dx.doi.org/10.1016/S0936-6555(97)80001-5]
[42]
Behnia M, Foster R, Einhorn LH, Donohue J, Nichols CR. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer 2000; 36(4): 472-5.
[http://dx.doi.org/10.1016/S0959-8049(99)00316-0] [PMID: 10717522]
[43]
Mano MS, Guimarães JLM, Sutmöller SFMC, Reiriz AB, Sutmöller CSSC, Di Leo A. Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report. Sao Paulo Med J 2006; 124(6): 343-5.
[http://dx.doi.org/10.1590/S1516-31802006000600009] [PMID: 17322957]
[44]
Hartmann JT, Lipp H. Toxicity of platinum compounds. Expert Opin Pharmacother 2003; 4(6): 889-901.
[http://dx.doi.org/10.1517/14656566.4.6.889]
[45]
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009; 219(3): 177-86.
[http://dx.doi.org/10.1620/tjem.219.177] [PMID: 19851045]
[46]
Tassinari D, Sartori S, Drudi G, et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann Oncol 1997; 8(12): 1263-7.
[http://dx.doi.org/10.1023/A:1008231521553] [PMID: 9496393]
[47]
McGuire WP, Blessing JA, DiSaia PJ, Buchsbaum HJ. Phase II trial of acivivin in patients with advanced epithelial ovarian carcinoma. Invest New Drugs 1986; 4(1): 49-52.
[http://dx.doi.org/10.1007/BF00172016] [PMID: 3700040]
[48]
Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol 1983; 12(6): 365-9.
[PMID: 6686617]
[49]
Nielsen E, Brant J. Chemothreapy-induced neurotoxicity. Oncology Nursing Update AJN 2002; 16-9.
[http://dx.doi.org/10.1007/s11910-016-0686-x]
[50]
Blöchl-Daum B, Pehamberger H, Kurz C, et al. Effects of cisplatin on urinary thromboxane B2 excretion. Clin Pharmacol Ther 1995; 58(4): 418-24.
[http://dx.doi.org/10.1016/0009-9236(95)90055-1] [PMID: 7586934]
[51]
Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 2003; 13(6): 619-26.
[http://dx.doi.org/10.1097/00008390-200312000-00012] [PMID: 14646626]
[52]
Higa GM, Wise TC, Crowell EB. Severe, disabling neurologic toxicity following cisplatin retreatment. Ann Pharmacother 1995; 29(2): 134-7.
[http://dx.doi.org/10.1177/106002809502900206] [PMID: 7756711]
[53]
Wang XL, Lin FL, Xu W, Wang C, Wang QQ, Jiang RW. Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. J Ethnopharmacol 2022.288114938
[http://dx.doi.org/10.1016/j.jep.2021.114938] [PMID: 34999144]
[54]
Wellenberg A, Weides L, Kurzke J, et al. Use of C. elegans as a 3R-compliant in vivo model for the chemoprevention of cisplatin-induced neurotoxicity. Exp Neurol 2021.341113705
[http://dx.doi.org/10.1016/j.expneurol.2021.113705] [PMID: 33753139]
[55]
Calhoun EA, Bennett CL, Peeples PA, et al. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol 1998; 71(3): 369-75.
[http://dx.doi.org/10.1006/gyno.1998.5189] [PMID: 9887233]
[56]
Piccolini VM, Esposito A, Dal Bo V, et al. Cerebellum neurotransmission during postnatal development: [Pt(O,O′-acac)(γ-acac)(DMS)] vs cisplatin and neurotoxicity. Int J Dev Neurosci 2015; 40(1): 24-34.
[http://dx.doi.org/10.1016/j.ijdevneu.2014.10.006] [PMID: 25450526]
[57]
Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum 2004; 31(3): 615-23.
[http://dx.doi.org/10.1188/04.ONF.615-623] [PMID: 15146227]
[58]
Cerri S, Piccolini VM, Santin G, et al. The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum. Neurotoxicol Teratol 2011; 33(2): 273-81.
[http://dx.doi.org/10.1016/j.ntt.2010.09.005] [PMID: 20883777]
[59]
Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 2006; 6(7): 973-82.
[http://dx.doi.org/10.1586/14737140.6.7.973] [PMID: 16831070]
[60]
Leo M, Schmitt LI, Jastrow H, Thomale J, Kleinschnitz C, Hagenacker T. Cisplatin alters the function and expression of N-type voltage-gated calcium channels in the absence of morphological damage of sensory neurons. Mol Pain 2017.131744806917746565
[http://dx.doi.org/10.1177/1744806917746565] [PMID: 29166837]
[61]
Bernocchi G, Fanizzi FP, De Pascali SA, et al. Neurotoxic Effects of Platinum Compounds: Studies in vivo on Intracellular Calcium Homeostasis in the Immature Central Nervous System. Toxics 2015; 3(2): 224-48.
[http://dx.doi.org/10.3390/toxics3020224] [PMID: 29056659]
[62]
Lacinová L. Voltage-dependent calcium channels. Gen Physiol Biophys 2005; 24.
[PMID: 16096350]
[63]
Unel CC, Erol K. The Role of Ionic Homeostasis in Cisplatin-Induced Neurotoxicity: A Preliminary Study. Eurasian J Med 2018; 50(2): 81-5.
[http://dx.doi.org/10.5152/eurasianjmed.2018.17233] [PMID: 30002572]
[64]
Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010; 6: 15.
[http://dx.doi.org/10.1186/1744-8069-6-15] [PMID: 20205720]
[65]
Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxi-city and preventive strategies: past, present, and future. Oncologist 2015; 20(4): 411-32.
[http://dx.doi.org/10.1634/theoncologist.2014-0044] [PMID: 25765877]
[66]
Podratz JL, Knight AM, Ta LE, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 2011; 41(3): 661-8.
[http://dx.doi.org/10.1016/j.nbd.2010.11.017] [PMID: 21145397]
[67]
Liu N, Zhou S, Olatunji OJ, Wu Y. Nucleosides rich extract from Cordyceps cicadae alleviated cisplatin-induced neurotoxicity in rats: A behavioral, biochemical and histopathological study. Arab J Chem 2022; 15(1)103476
[http://dx.doi.org/10.1016/j.arabjc.2021.103476]
[68]
Wellenberg A, Brinkmann V, Bornhorst J, Ventura N, Honnen S, Fritz G. Cisplatin-induced neurotoxicity involves the disruption of serotonergic neurotransmission. Pharmacol Res 2021.174105921
[http://dx.doi.org/10.1016/j.phrs.2021.105921] [PMID: 34601079]
[69]
Kurian A, Babu B, Punnoose B, Chacko CS, Rao M, Chand S, et al. Cisplatin-induced peripheral neuropathy: an observational descriptive study. International Journal of Research in Pharmaceutical Sciences 2021; 11(3): 3585-9.
[http://dx.doi.org/10.26452/ijrps.v11i3.2515]
[70]
Alberti P. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol 2019; 15(6): 487-97.
[http://dx.doi.org/10.1080/17425255.2019.1622679] [PMID: 31116618]
[71]
Skaali T, Fosså SD, Andersson S, et al. A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 2011; 22(5): 1062-70.
[http://dx.doi.org/10.1093/annonc/mdq553] [PMID: 21048038]
[72]
Nitipir C, Baetu A, Voinea A, et al. Peripheral Neurotoxicity Induced by Taxanes, Cisplatin, Oxaliplatin, Fluoropyrimidines and Vinorelbine. A clinical perspective. Rev Chim 2018; 69(12): 3427-32.
[http://dx.doi.org/10.37358/RC.18.12.6763]
[73]
Stankovic JSK, Selakovic D, Mihailovic V, Rosic G. Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics-A Review. Int J Mol Sci 2020; 21(20): 1-26.
[http://dx.doi.org/10.3390/ijms21207753] [PMID: 33092125]
[74]
Leonetti C, Biroccio A, Gabellini C, et al. Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 2003; 104(2): 243-50.
[http://dx.doi.org/10.1002/ijc.10933] [PMID: 12569582]
[75]
Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41(12): 1746-50.
[http://dx.doi.org/10.1016/j.ejca.2005.04.028] [PMID: 16039110]
[76]
Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 2011; 16(3): 228-36.
[http://dx.doi.org/10.1111/j.1529-8027.2011.00351.x] [PMID: 22003937]
[77]
Chen CA, Lin H, Weng CS, et al. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer 2014; 50(18): 3161-7.
[http://dx.doi.org/10.1016/j.ejca.2014.10.006] [PMID: 25459394]
[78]
Li Y, Li Y, Li J, Pi G, Tan W. Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review. OncoTargets Ther 2014; 7: 1361-6.
[http://dx.doi.org/10.2147/OTT.S65774] [PMID: 25114574]
[79]
Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015; 16(3): 301-11.
[http://dx.doi.org/10.1016/S1470-2045(15)70004-5] [PMID: 25638326]
[80]
Xu Y, Shi X, Wang Y. Effects of Paclitaxel and Cisplatin Combined with Traditional Chinese Therapy on Serum Tumor Markers and Immunological Indexes in Advanced Epithelial Ovarian Cancer. Lat Am J Pharm 2021; 40(5): 921-5.
[81]
Collins C, Higano CS, Livingston RB, Griffin BR, Keppen MD, Miller TP. Cyclophosphamide, vincristine, cisplatin, VP-19 and radiation therapy in extensive small-cell lung cancer. Cancer Chemother Pharmacol 1989; 24(2): 128-32.
[http://dx.doi.org/10.1007/BF00263134] [PMID: 2543513]
[82]
Omura GA, Blessing JÁ, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15(1): 165-71.
[http://dx.doi.org/10.1200/JCO.1997.15.1.165] [PMID: 8996138]
[83]
Kataria PS, Kendre PP, Patel AA. Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction. J Pharmacol Pharmacother 2017; 8(1): 38-40.
[http://dx.doi.org/10.4103/jpp.JPP_182_16] [PMID: 28405136]
[84]
Warner E. Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 1995; 5(3): 161-9.
[http://dx.doi.org/10.1046/j.1525-1438.1995.05030161.x] [PMID: 11578472]
[85]
Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 1999; 5(4): 767-74.
[PMID: 10213211]
[86]
Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18(3): 623-31.
[http://dx.doi.org/10.1200/JCO.2000.18.3.623] [PMID: 10653877]
[87]
Dreicer R, Manola J, Roth BJ, et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000; 18(5): 1058-61.
[http://dx.doi.org/10.1200/JCO.2000.18.5.1058] [PMID: 10694557]
[88]
Dimopoulos MA, Papadimitriou CA, Sarris K, et al. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol 2002; 85(3): 476-82.
[http://dx.doi.org/10.1006/gyno.2002.6649] [PMID: 12051877]
[89]
Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22(11): 2159-66.
[http://dx.doi.org/10.1200/JCO.2004.07.184] [PMID: 15169803]
[90]
Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007; 17(2): 387-93.
[http://dx.doi.org/10.1111/j.1525-1438.2007.00794.x] [PMID: 17362317]
[91]
Mountzios G, Dimopoulos MA, Bamias A, et al. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2009; 20(8): 1362-8.
[http://dx.doi.org/10.1093/annonc/mdn797] [PMID: 19457937]
[92]
Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1998; 71(3): 410-5.
[http://dx.doi.org/10.1006/gyno.1998.5206] [PMID: 9887240]
[93]
Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25(4): 437-43.
[http://dx.doi.org/10.1200/JCO.2006.07.3494] [PMID: 17264340]
[94]
Wiernik PH, Yeap B, Vogl SE, et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992; 10(1): 1-9.
[http://dx.doi.org/10.3109/07357909209032783] [PMID: 1735009]
[95]
Jassem J, Gyergyay F, Kerpel-Fronius S, et al. Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study. Cancer Chemother Pharmacol 1993; 31(6): 489-94.
[http://dx.doi.org/10.1007/BF00685041] [PMID: 8453690]
[96]
Grunberg SM, Crowley JJ, Livingston RB, et al. Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study. Cancer Chemother Pharmacol 1991; 28(3): 211-3.
[http://dx.doi.org/10.1007/BF00685511] [PMID: 1649706]
[97]
Wadler S, Beitler JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. J Clin Oncol 1993; 11(8): 1511-6.
[http://dx.doi.org/10.1200/JCO.1993.11.8.1511] [PMID: 8393096]
[98]
Fleming GF, Fowler JM, Waggoner SE, et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19(4): 1021-9.
[http://dx.doi.org/10.1200/JCO.2001.19.4.1021] [PMID: 11181665]
[99]
Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23(15): 3562-7.
[http://dx.doi.org/10.1200/JCO.2005.01.057] [PMID: 15908667]
[100]
Gradishar WJ, Stephenson P, Glover DJ, et al. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). Cancer 2001; 92(10): 2517-22.
[http://dx.doi.org/10.1002/1097-0142(20011115)92:10<2517::AIDCNCR1602>3.0.CO;2-Z] [PMID: 11745184]
[101]
Long HJ III, Monk BJ, Huang HQ, et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol 2006; 100(3): 537-43.
[http://dx.doi.org/10.1016/j.ygyno.2005.09.023] [PMID: 16216315]
[102]
Markman M. Limits to the “benefits” from our oncologic interventions: a case report. Gynecol Oncol 2000; 78(2): 261-2.
[http://dx.doi.org/10.1006/gyno.2000.5866] [PMID: 10926815]
[103]
Moore DH, Donnelly J, McGuire WP, et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003; 21(22): 4207-13.
[http://dx.doi.org/10.1200/JCO.2003.02.086] [PMID: 14615449]
[104]
Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II Study of Cisplatin and Vinorelbine in Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol 22(16): 3340-4.
[http://dx.doi.org/10.1200/JCO.2004.12.006]
[105]
Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18(1): 106-15.
[http://dx.doi.org/10.1200/JCO.2000.18.1.106] [PMID: 10623700]
[106]
Gounaris I, Iddawela M, Parkinson C, et al. Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse? Anticancer Drugs 2016; 27(3): 239-44.
[http://dx.doi.org/10.1097/CAD.0000000000000320] [PMID: 26575000]
[107]
Walker JL, Brady MF, Wenzel L, et al. Randomized Trial of Intravenous versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2019; 37(16): 1380-90.
[http://dx.doi.org/10.1200/JCO.18.01568] [PMID: 31002578]
[108]
Steffen McLouth LE, Zhao F, Owonikoko TK, et al. Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. Cancer Med 2020; 9(20): 7511-23.
[http://dx.doi.org/10.1002/cam4.3416] [PMID: 32860331]
[109]
Yokota T, Shibata M, Hamauchi S, et al. Feasibility and efficacy of chemoradiotherapy with concurrent split-dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for locally advanced head and neck cancer. Mol Clin Oncol 2020; 13(4): 35.
[http://dx.doi.org/10.3892/mco.2020.2105] [PMID: 32802331]
[110]
Abdel-Rahman LH, Adam MS, Abu-Dief AM, Ahmed HE, Nafady A. Non-Linear Optical Property and Biological Assays of Therapeutic Potentials Under in vitro Conditions of Pd(II), Ag(I) and Cu(II) Complexes of 5-Diethyl amino-2-({2-[(2-hydroxy-Benzylidene)-amino]-phenylimino}-methyl)-phenol. Molecules 2020; 25(21): 5089.
[http://dx.doi.org/10.3390/molecules25215089] [PMID: 33147867]
[111]
Abdel-Rahman LH, Adam MSS, Al-Zaqri N, Shehata MR, Ahmed HE, Mohamed SK. Synthesis, characterization, biological and docking studies of ZrO(II), VO(II) and Zn(II) complexes of a halogenated tetra-dentate Schiff base. Arab J Chem 2022; 15(5)103737
[http://dx.doi.org/10.1016/j.arabjc.2022.103737]
[112]
Abu-Dief AM, Abdel-Rahman LH, Abdel-Mawgoud AAH. A robust in vitro Anticancer, Antioxidant and Antimicrobial Agents Based on New Metal-Azomethine Chelates Incorporating Ag(I), Pd (II) and VO (II) Cations: Probing the Aspects of DNA Interaction. Appl Organomet Chem 2020; 34(2)e5373
[http://dx.doi.org/10.1002/aoc.5373]
[113]
Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016; 8(5): 776-91.
[http://dx.doi.org/10.1002/wnan.1390] [PMID: 26848041]
[114]
Anees LM, Abdel-Hamid GR, Elkady AA. A nano based approach to alleviate cisplatin induced nephrotoxicity. Int J Immunopathol Pharmacol 2021.3520587384211066441
[http://dx.doi.org/10.1177/20587384211066441] [PMID: 34915755]
[115]
Saddik MS, Elsayed MMA, Abdelkader MSA, et al. Novel Green Biosynthesis of 5-Fluorouracil Chromium Nanoparticles Using Harpullia pendula Extract for Treatment of Colorectal Cancer. Pharmaceutics 2021; 13(2): 226.
[http://dx.doi.org/10.3390/pharmaceutics13020226] [PMID: 33562032]
[116]
Abu-Dief A, Alsehli M, Al-Enizi A, Nafady A. Recent Advances in Mesoporous Silica Nanoparticles for Targeted Drug Delivery applications. Curr Drug Deliv 2021; 19(4): 436-50.
[http://dx.doi.org/10.2174/1567201818666210708123007] [PMID: 34238185]

Rights & Permissions Print Cite
Article Metrics
21
3
© 2024 Bentham Science Publishers | Privacy Policy